Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129522 | 0.84 | HPGD (0.41) | HPGDSMN1; SMN2L3MBTL1NPC1ALDH1A1 | |
| SCHEMBL129116 | 0.78 | — | — | |
| SCHEMBL21859753 | 0.77 | HPGD (0.46) | HPGDSMN1; SMN2L3MBTL1SLC6A2NPC1 | |
| SCHEMBL1697616 | 0.77 | HPGD (0.55) | HPGDSMN1; SMN2L3MBTL1SLC6A2NPC1 | |
| SCHEMBL31078868 | 0.77 | HPGD (0.55) | HPGDSMN1; SMN2L3MBTL1SLC6A2NPC1 | |
| SCHEMBL131465 | 0.77 | PDE1A (0.46) | HPGDSMN1; SMN2L3MBTL1SLC6A2NPC1 | |
| SCHEMBL128656 | 0.76 | SLC13A5 (0.47) | HPGDSMN1; SMN2L3MBTL1SLC6A2NPC1 | |
| SCHEMBL1842773 | 0.75 | HPGD (0.53) | HPGDSMN1; SMN2L3MBTL1SLC6A2NPC1 | |
| SCHEMBL12948866 | 0.75 | SLC13A5 (0.52) | HPGDSMN1; SMN2L3MBTL1NPC1TSHR | |
| SCHEMBL1480240 | 0.75 | HPGD (0.44) | HPGDSMN1; SMN2L3MBTL1SLC6A2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232994-A1 | Bicyclic thiophene derivatives and combinatorial libraries thereof | LION BIOSCIENCE AG (DE) | 2003-12-18 | — | — | US | claimed |
| CN-110914280-B | 6H-thieno [2,3-e ] [1,2,4] triazolo [3,4-c ] [1,2,4] triazab derivatives | 阿尤米制药公司 | 2024-05-03 | — | — | CN | disclosed |
| US-11186588-B2 | 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2021-11-30 | — | — | US | disclosed |
| US-20210130367-A1 | 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2021-05-06 | — | — | US | disclosed |
| EP-3640253-A1 | 6H-THIENO[2,3-E][1,2,4]TRIAZOLO[3,4-C][1,2,4]TRIAZEPINE DERIVATIVE | AYUMI Pharmaceutical Corporation (JP) | 2020-04-22 | — | — | EP | disclosed |
| CN-110914280-A | 6H-thieno [2,3-e ] [1,2,4] triazolo [3,4-c ] [1,2,4] triaza derivatives | 阿尤米制药公司 | 2020-03-24 | — | — | CN | disclosed |
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
| US-20030232994-A1 | Bicyclic thiophene derivatives and combinatorial libraries thereof | LION BIOSCIENCE AG (DE) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130367-A1 | 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE | BRD4, BRD3, BRD2 | HPGD 3500/4885SMN1; SMN2 3608/4885L3MBTL1 927/4885 |
| US-20030232994-A1 | Bicyclic thiophene derivatives and combinatorial libraries thereof | CXCR2, BICRA, CXCR1 | HPGD 3319/4885SMN1; SMN2 4658/4885L3MBTL1 3078/4885 |
| US-11186588-B2 | 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative | BRD4, BRD3, BRD2 | HPGD 3500/4885SMN1; SMN2 3608/4885L3MBTL1 927/4885 |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | HPGD 450/4885SMN1; SMN2 4613/4885L3MBTL1 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.